2 February 2009 - Enzymotec Ltd. (the “Company”) announced today that it successfully completed Series B1 investment round, raising $11 million. The round was led by the Company's existing shareholders (Galam Ltd, Ofer Hi-Tech Investments Ltd. and Millennium II Materials Technology Fund L.P.) and by a new investor – Arancia International Inc.
In addition, the Company is finalizing a new $7 million line of credit (of which $3m were already received) from a leading Israeli bank.
“The successful completion of the financial round validates the strength and potential of Enzymotec, particularly given current economic conditions" said Dr. Ariel Katz, President and CEO of Enzymotec. "This additional funding will enable us to complete the construction of our new plant in Migdal HaEmek, Israel, with increased capacity and will enable us to enhance our research and development activities in the next years“.
Mr. Luis Aranguren, Arancia Industrial S.A. de C.V Executive President said: "We are excited to join Enzymotec and be a part of the development and production of lipid-based innovative health solutions."